Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Alnylam Pharmaceuticals, Inc.'s quarterly P/E stands at 54.8x. EV/EBITDA has compressed 73.7% YoY to 74.3x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 127.00 | 54.78 | 72.56 | 61.96 | — | — | — | — | — | — | — | 38.50 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 10.63 | 9.80 | 12.35 | 12.54 | 13.66 | 14.73 | 12.75 | 17.65 | 11.67 | 9.53 | 13.67 | 7.75 | 18.57 |
| — | -33.5% | -3.2% | -29.0% | +17.1% | +54.5% | -6.7% | +127.8% | -37.2% | -51.0% | -37.5% | -66.5% | -5.3% | |
| P/B Ratio | 50.50 | 42.53 | 68.67 | 267.77 | 168.75 | 303.33 | 451.03 | 1093.10 | — | — | — | — | — |
| — | -86.0% | -84.8% | -75.5% | — | — | — | — | — | — | — | — | — | |
| P/FCF | 84.84 | 234.93 | 96.59 | 50.03 | 75.82 | — | — | 223.75 | 66.29 | — | — | 16.99 | — |
| — | — | — | -77.6% | +14.4% | — | — | +1217.2% | — | — | — | — | — | |
| EV / EBITDA | 70.17 | 74.33 | 92.64 | 40.89 | — | 282.60 | — | — | 127.86 | — | — | 25.90 | — |
| — | -73.7% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 77.96 | 74.33 | 102.14 | 55.10 | 2245.91 | — | — | — | 368.20 | — | — | 32.39 | — |
| — | — | — | — | +510.0% | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Alnylam Pharmaceuticals, Inc.'s operating margin was 23.0% in Q1 2026, up 11.0 pp QoQ and up 20.0 pp YoY. The trailing four-quarter average of 15.6% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 7.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.8% | 81.9% | 75.6% | 84.2% | 81.5% | 88.0% | 82.7% | 82.9% | 89.6% | 86.7% | 80.5% | 88.8% | 73.2% |
| — | -7.0% | -8.6% | +1.6% | -9.0% | +1.6% | +2.7% | -6.7% | +22.4% | +4.6% | -5.0% | +5.1% | -10.5% | |
| Operating Margin | 13.5% | 23.0% | 12.0% | 29.5% | -2.1% | 3.0% | -17.7% | -15.4% | 7.4% | -8.8% | -26.5% | 28.5% | -72.1% |
| — | +656.5% | +167.7% | +291.9% | -128.4% | +134.6% | +33.0% | -153.9% | +110.2% | +81.3% | +53.0% | +129.2% | +15.4% | |
| Net Margin | 8.4% | 17.6% | 17.0% | 20.1% | -8.6% | -9.7% | -14.1% | -22.3% | -2.6% | -13.3% | -31.4% | 19.7% | -86.6% |
| — | +282.4% | +220.3% | +190.3% | -234.7% | +27.5% | +55.0% | -213.1% | +97.0% | +75.5% | +49.4% | +112.8% | +29.8% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 73.3% | 22.1% | 36.4% | 103.6% | -36.2% | -63.0% | -168.5% | -761.9% | — | — | — | — | — |
| — | +135.1% | +121.6% | +113.6% | — | — | — | — | — | — | — | — | — | |
| ROA | 6.8% | 4.1% | 3.8% | 5.3% | -1.5% | -1.4% | -2.0% | -2.7% | -0.4% | -1.7% | -3.6% | 4.1% | -8.1% |
| — | +400.1% | +291.4% | +296.3% | -250.1% | +21.1% | +44.8% | -166.6% | +94.7% | +65.7% | +38.6% | +134.5% | +0.9% | |
| ROIC | 33.4% | 38.5% | 42.7% | 28.6% | -0.7% | 0.7% | -4.5% | -3.4% | 2.1% | -1.9% | -9.9% | 89.5% | -54.1% |
| — | +5093.2% | +1048.8% | +942.3% | -131.7% | +139.0% | +54.6% | -103.8% | +103.8% | +94.2% | +83.2% | +279.0% | -173.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Alnylam Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 8.4x, down from 8.8x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 7 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.62 | 1.18 | 1.62 | 5.59 | 10.93 | 23.58 | 40.89 | 84.26 | — | — | — | — | — |
| — | -95.0% | -96.0% | -93.4% | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 2.29 | 8.36 | 8.80 | 3.43 | — | 83.81 | — | — | 42.57 | — | — | 5.76 | — |
| — | -90.0% | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.76 | 3.13 | 2.76 | 2.54 | 2.80 | 3.04 | 2.78 | 2.75 | 3.01 | 3.17 | 3.08 | 3.14 | 3.20 |
| — | +2.9% | -0.6% | -7.6% | -6.8% | -4.3% | -9.9% | -12.5% | -6.1% | -15.9% | -12.1% | -9.7% | -14.8% | |
| Quick Ratio | 2.71 | 3.06 | 2.71 | 2.49 | 2.75 | 2.98 | 2.71 | 2.69 | 2.93 | 3.07 | 2.99 | 3.04 | 3.07 |
| — | +2.9% | -0.2% | -7.2% | -6.2% | -3.1% | -9.3% | -11.7% | -4.8% | -14.1% | -10.4% | -8.7% | -15.2% | |
| Interest Coverage | 1.99 | 2.20 | 1.02 | 6.38 | 0.12 | -0.08 | -3.98 | -2.16 | 0.66 | -0.80 | -3.39 | 5.88 | -8.13 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying ALNY stock.
Alnylam Pharmaceuticals, Inc.'s current P/E is 127.0x. The average P/E over the last 3 quarters is 63.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Alnylam Pharmaceuticals, Inc.'s current operating margin is 13.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Alnylam Pharmaceuticals, Inc.'s business trajectory between earnings reports.